Arthritis Reactive

Overview Forums Topics Doctor Questions eHealthpedia
Ask our Community
Members
eHealthpedia Articles
Arthritis Diagnosis
Signs and symptoms of rheumatic diseases are common to many different diseases. Diagnose arthritis correctly using these step-by-step diagnosis instructions.
What is arthritis?
Arthritis is the most common cause of disability in the United States. Learn more about types of arthritis here.
Rheumatoid Arthritis Diagnosis
Whether you see your family doctor or a rheumatologist about rheumatoid arthritis, know what to expect from your appointment.
Osteoarthritis Diagnosis
Doctors must rule out other possible causes of joint pain before diagnosing osteoarthritis. Learn more about what tests you can expect during an office visit.
Joint Pain Diagnosis
Which medical doctor should you see for joint pain? And what tests can you expect during diagnosis? A full review of medical history and exams to help get ready
More
Topics
Snozzle
Snozzle / Arthritis
carrie38
carrie38 / Arthritis
carrie38
carrie38 / Arthritis
More
Medical Experts
Dr. Kokil Mathur
General Medicine
Madhumita Paul
General Medicine, Women's Health
Doctor Answers
Dr. Nikola Gjuzelov
Dr. Nikola Gjuzelov / Arthritis
Dr. Harpreet Singh
Dr. Harpreet Singh / HIV and AIDS
Dr. Nikola Gjuzelov
Dr. Nikola Gjuzelov / Arthritis
Dr. Harpreet Singh
Dr. Harpreet Singh / Arthritis
More
News
Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex announced results from a Phase 2a trial of an investigational selective oral JAK3 inhibitor, VX-509, for rheumatoid arthritis.
TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type ...
TAIPEI, Taiwan, Sept. 7, 2011 /PRNewswire-Asia/ -- TWi Biotechnology, Inc. announces the successful patient recruitment for the multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb clinical trial of AC-201 for t
Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
HAYWARD, Calif., Sept. 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that the U.S. Patent and Trademark Office has
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of ...
EAST HANOVER, N.J., Sept. 16, 2011 /PRNewswire/ -- Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory dise
Novartis study showed ACZ885 provided substantial symptom relief in 84% of patients with the most serious form of ...
Novartis International AG / Novartis study showed ACZ885 provided substantial symptom relief in 84% of patients with the most serious form of childhood arthritis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible …